| Literature DB >> 32714468 |
Getenet Dessie1, Fasil Wagnew2, Henok Mulugeta2, Amare Belachew1, Ayenew Negesse3, Getachew Mullu Kassa4, Tesfa Dejenie Habtewold5, Kaley Parchinski6.
Abstract
BACKGROUND: Diabetes mellitus (DM) is a major public health problem worldwide that was estimated to have affected the lives of 425 million people globally in 2017. The prevalence and mortality rates of DM have increased rapidly in low- and middle-income countries with an estimated 2.6 million cases of DM occurring in Ethiopia alone in 2015.Entities:
Keywords: Adherence; Antidiabetic medication; Ethiopia; Meta-analysis
Year: 2020 PMID: 32714468 PMCID: PMC7378857 DOI: 10.1016/j.curtheres.2020.100585
Source DB: PubMed Journal: Curr Ther Res Clin Exp ISSN: 0011-393X
Characteristics of the included studies for meta-analysis (2013–2018, Ethiopia).
| Study No. | Author name | Year of publication | Type of DM | Region | Type(s) of medication | Study design | Sample size | How good adherence was measured | Proportion of good adherence (%) | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Teklay, et al | 2013 | Type 2 | Oromia | Oral hypoglycemic agent and insulin | Cross-sectional | 267 | MMAS | 75.7 | 6 |
| 2 | Gelaw, et al | 2014 | Type 1, 2 | Oromia | Oral hypoglycemic agent and insulin | Cross-sectional | 270 | 4-point adherence survey | 72.2 | 6.5 |
| 3 | Gelaw, et al | 2014 | Type 1, 2 | Oromia | Oral and insulin | Cross-sectional | 275 | 4-point adherence survey | 78.2 | 7 |
| 4 | Abebe, et al | 2015 | Type 1, 2 | Amhara | Oral hypoglycemic agent and insulin | Cross-sectional | 407 | MMAS | 45.9 | 7 |
| 5 | Mamo, et al | 2016 | Type 1, 2 | Addis Ababa | Oral hypoglycemic agent and insulin | Cross-sectional | 660 | Adherence survey | 91.7 | 6.5 |
| 6 | Kassahun, et al | 2016 | Type 1, 2 | Oromia | Oral hypoglycemic agent and insulin | Cross-sectional | 285 | Self-reported non-adherence survey | 68.8 | 7 |
| 7 | Girma Bizu, et al | 2016 | Type 2 | Addis Ababa | Oral hypoglycemic agent | Cross-sectional | 155 | MMAS | 49 | 7 |
| 8 | Abebaw, et al | 2016 | Type 2 | Amhara | Oral hypoglycemic agent and insulin | Cross-sectional | 288 | 5-point MMAS | 85.1 | 7 |
| 9 | Sorato, et al | 2016 | Type 2 | SNNP | Oral hypoglycemic agent and insulin | Cross-sectional | 194 | 8-point MMAS | 84 | 7 |
| 10 | Tsehay, et al | 2016 | Type 2 | Addis Ababa | Oral hypoglycemic agent and insulin | Cross-sectional | 322 | 4-point MMAS | 66.8 | 7 |
| 11 | Jemal, et al | 2017 | Type 2 | Harar | Oral hypoglycemic agent and insulin | Cross-sectional | 200 | 4-point MMAS | 70.4 | 7 |
| 12 | Ali, et al | 2017 | Type 1, 2 | Addis Ababa | Oral hypoglycemic agent and insulin | Cross-sectional | 146 | 8-point MMAS | 54.8 | 6 |
| 13 | Tadele, et al | 2017 | Type 1 | Oromia | Insulin | Cross-sectional | 256 | Self-reported adherence survey | 30.9 | 7 |
| 14 | Mesfin, et al | 2017 | Type 2 | Addis Ababa | Oral hypoglycemic agent and insulin | Cross-sectional | 275 | MMAS | 51.3 | 6.5 |
| 15 | Gerada, et al | 2017 | Type 1, 2 | Addis Ababa | Insulin | Cross-sectional | 378 | Non-adherence described as taking <80% of prescribed insulin injection | 66.9 | 7 |
| 16 | Berhe, et al | 2017 | Type 2 | Tigray | Oral hypoglycemic agent and insulin | Cross-sectional | 343 | Adherence = taking >80% of prescribed treatment | 83.7 | 7 |
| 17 | Tewabe, et al | 2018 | Type 1 | Amhara | Insulin | Cross-sectional | 182 | Adherence = taking >80% of prescribed treatment | 59.9 | 7 |
| 18 | Wabe, et al | 2018 | Type 2 | Oromia | Oral hypoglycemic agent and insulin | Cross-sectional | 384 | Adequate glycemic control was defined as patients with fasting plasma glucose level between 90 mg/dL and 100 mg/dL | 61.9 | 6.5 |
| 19 | Bonger, et al | 2018 | Type 2 | Addis Ababa | Oral hypoglycemic agent and insulin | Cross-sectional | 422 | Self-reported adherence survey | 95.7 | 6 |
| 20 | Abate TW | 2019 | Type 1, 2 | Amhara | Insulin | Cross-sectional | 416 | MMAS | 68.8 | 6 |
| 21 | Ayele AA, et al | 2019 | Type 2 | Amhara | Insulin | Cross-sectional | 275 | Adherence = taking >50% of prescribed treatment during past 3 d | 70.5 | 7 |
| 22 | Wabe NT, et al | 2011 | Type 2 | Oromia | Oral hypoglycemic agent and insulin | Cross-sectional | 384 | MMAS | 41.8 | 6.5 |
| 23 | Gelaw, BK et al | 2014 | Type 2 | Oromia | Oral hypoglycemic agent and insulin | Cross-sectional | 113 | Self-reported adherence survey | 72 | 6 |
| 24 | Yohannes Tekalegn, et al | 2017 | Type 2 | Addis Ababa | Oral hypoglycemic agent and insulin | Cross-sectional | 412 | 87.6 | 6 | |
| 25 | Fseha B, et al | 2017 | Type 2 | Tigray | Oral hypoglycemic agent and insulin | Cross-sectional | 200 | Adherence = taking >50% of prescribed treatment during past 3 d | 61 | 6 |
| 26 | Tesfaye DK, et al | 2015 | Type 1, 2 | SNNP | Oral hypoglycemic agent and insulin | Cross-sectional | 247 | SDSCA | 91.9 | 6.5 |
DM = diabetes mellitus; NOS = Newcastle-Ottawa scale; MMAS = Morisky Medication Adherence Scale; SDSCA = Summary Diabetes Self-Care Activity.
Figure 1Flow diagram showing the procedure of selecting studies for meta-analysis in Ethiopia 2013–2019.
Meta-regression results on selected variables in studies conducted from 2013 to 2019 in Ethiopia.
| Variable | Coefficient | |
|---|---|---|
| Publication year | –3.5 | 0.762 |
| Sample size | 0.052 | 0.712 |
| Region | ||
| Addis Ababa | –23.1 | 0.795 |
| Amhara | –27.43 | 0.766 |
| Harar | –13.3 | 0.905 |
| Oromia | –33.5 | 0.705 |
| SNNP | 0.3 | 0.998 |
| Tigray | 83.7 | 0.336 |
Figure 2Forest plot showing the proportion of reported medication adherence among diabetic patients in Ethiopia (2013–2019).
Figure 3Forest plot showing the association between good diabetic medication adherence and the presence of a glucometer among diabetic patients in Ethiopia from 2013 to 2019.
Figure 4Forest plot showing the association between a good level of diabetic medication adherence and geographic location of a diabetic patient's residence in Ethiopia from 2013 to 2019.